Influences of intravesical BCG therapy in lower urinary tract symptom

Influences of intravesical BCG therapy in lower urinary tract symptom - Influences of intravesical BCG therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040457

Enrollment

Registered

2020-05-20

Start date

2020-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma in situ of the bladder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who receive intravesical BCG therapy for urothelial carcinoma in situ of the bladder

Exclusion criteria

Exclusion criteria: Subjects deemed inappropriate to participate in this study by the principle investigator

Design outcomes

Primary

Measure	Time frame
Influences of intravesical BCG therapy on local symptoms Before intravesical injection of BCG 2 weeks, 3 months, 6 months after intravesical BCG therapy	—

Secondary

Measure	Time frame
Influences of on systemic symptoms Discontinuation rate of intravesical BCG therapy and its reason Recurrence after intravesical BCG therapy	—

Countries

Japan

Contacts

Public ContactYasuyuki Kobayashi

Kinki Central Hospital of Mutual Aid Association of Public School Teachers Department of Urology

ya_su_koba@yahoo.co.jp072-781-3712

Outcome results